Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: Int J Cancer. 2016 Sep 8;139(12):2655–2670. doi: 10.1002/ijc.30288

Table 2.

Unconditional ASSET two-sided meta-analysis results across five cancer typesa

Gene (Chr.) Ref: MA MAF Combined P-value Positively Associated
Inversely Associated
Cancer types
 SNP Position OR (95% CI) P-value OR (95% CI) P-value Positively Associated Negatively Associated
DCLRE1B (Chr. 1)
 rs974404 114382025 T:G 0.449 9.19E-06e 1.04 (1.01–1.07) 2.47E-02f 0.94 (0.91–0.97) 2.43E-05e Breast, Ovarian Prostate, Lung
 rs7523862b 114443419 G:A 0.379 1.09E-05e 0.94 (0.91–0.97) 1.17E-05e Prostate, Lung
 rs12144215 114187155 G:T 0.131 1.50E-05e 0.90 (0.87–0.94) 2.11E-06e Colorectal, Prostate
TERC (Chr. 3)
 rs80304993 170097606 G:A 0.230 6.54E-15e 0.82 (0.78–0.86) 1.51E-15e Prostate
 rs71277158 169999216 T:G 0.162 8.88E-15e 0.80 (0.76–0.84) 3.64E-16e Prostate
 rs76925190 170066339 A:C 0.173 1.25E-14e 0.80 (0.76–0.84) 6.27E-16e Prostate
 rs75982374 170063227 A:G 0.140 4.65E-13e 0.79 (0.74–0.84) 2.62E-14e Prostate
 rs55953261 170121598 G:A 0.488 4.58E-09e 0.89 (0.85–0.92) 3.57E-09e Prostate
 rs77085460 170127536 A:G 0.063 7.30E-09e 0.76 (0.70–0.83) 3.81E-10e Prostate
 rs59758024c 170119352 A:T 0.447 9.03E-09e 1.12 (1.08–1.17) 7.08E-09e Prostate
 rs75316749 168761423 A:G 0.041 1.38E-06e 1.14 (1.08–1.20) 1.38E-06e Colorectal, Breast, Ovarian, Lung
 rs75313056 170017609 G:A 0.082 1.51E-08e 0.80 (0.74–0.86) 9.54E-10e Prostate
 rs12487040 170103592 T:C 0.372 1.70E-08e 1.05 (1.01–1.09) 2.46E-02f 0.89 (0.85–0.93) 3.13E-08e Breast, Ovarian Prostate
 rs10804842 170135700 T:C 0.234 1.73E-08e 0.86 (0.82–0.90) 1.94E-09e Prostate
 rs969217 170159134 C:T 0.391 2.73E-07e 1.06 (1.02–1.11) 2.62E-03 0.90 (0.87–0.94) 5.47E-06e Breast Prostate
 rs77964281 169916180 T:C 0.117 3.49E-07e 0.85 (0.80–0.90) 2.65E-08e Prostate
 rs62293480 170106672 G:T 0.388 1.35E-06e 0.89 (0.84–0.93) 5.97E-07e Prostate
 rs10936633 170158128 G:A 0.493 1.49E-06e 0.90 (0.87–0.94) 7.74E-07e Prostate
 rs9865021 170146881 C:T 0.487 2.48E-06e 1.10 (1.06–1.14) 2.11E-06e Prostate
 rs74677551 168861788 T:G 0.032 3.20E-06e 1.15 (1.08–1.22) 3.20E-06e Colorectal, Breast, Prostate, Ovarian, Lung
 rs9809168 168803900 T:C 0.033 1.20E-05e 1.15 (1.08–1.22) 1.20E-05e Colorectal, Breast, Ovarian, Lung
 rs2901621 170057704 G:C 0.098 1.77E-05e 0.93 (0.91–0.96) 3.52E-06e Colorectal, Prostate
GAR1 (Chr. 4)
 rs17042238d 111745854 A:G 0.003 6.33E-06e 0.04 (0.01–0.16) 6.33E-06e Prostate
TERT-CLPTM1L (Chr. 5)
 rs37004b 1356684 C:T 0.239 2.27E-11e 0.84 (0.81–0.88) 1.29E-12e Lung
 rs37005b 1356450 C:T 0.460 1.98E-10e 0.87 (0.84–0.91) 9.85E-12e Lung
 rs3816659b 1317820 G:A 0.441 2.44E-10e 0.88 (0.85–0.91) 9.97E-12e Lung
 rs2736100b 1286516 C:A 0.500 3.38E-10e 1.05 (1.01–1.09) 1.72E-02f 0.90 (0.86–0.93) 7.54E-10e Colorectal, Prostate Lung
 rs7725218b 1282414 G:A 0.359 3.02E-09e 1.12 (1.07–1.17) 3.14E-07e 0.90 (0.85–0.96) 4.04E-04 Lung Prostate
 rs35953391b 1312329 C:T 0.201 6.44E-09e 0.87 (0.83–0.91) 1.43E-09e Lung
 rs2735940b 1296486 G:A 0.499 7.44E-09e 1.09 (1.05–1.14) 1.91E-05 0.93 (0.90–0.96) 1.70E-05 Lung Colorectal, Prostate
 rs2736099b 1287340 G:A 0.344 8.62E-09e 1.12 (1.08–1.17) 1.75E-07e 0.95 (0.92–0.98) 2.18E-03 Lung Colorectal, Breast, Prostate
 rs35029535 1284976 C:T 0.352 5.54E-08e 1.09 (1.03–1.15) 2.09E-03 0.92 (0.89–0.95) 1.28E-06e Prostate Breast, Ovarian, Lung
 rs7713218 1283312 G:A 0.497 5.78E-08e 1.10 (1.06–1.14) 6.60E-07e 0.95 (0.91–0.98) 4.23E-03 Ovarian, Lung Colorectal, Prostate
 rs10866498 1285162 C:T 0.472 6.36E-08e 1.05 (1.01–1.09) 6.76E-03 0.91 (0.88–0.94) 4.57E-07e Colorectal, Prostate Ovarian, Lung
 rs2735948b 1299213 G:A 0.418 7.70E-08e 0.88 (0.85–0.92) 5.56E-09e Lung
 rs36019446 1339890 A:G 0.484 1.57E-07e 0.88 (0.85–0.92) 1.05E-08e Lung
 rs2736098b 1294086 C:T 0.234 2.48E-07e 1.08 (1.04–1.12) 1.81E-04 0.93 (0.90–0.97) 7.16E-05 Prostate, Lung Colorectal, Breast, Ovarian
 rs7717443 1283486 C:T 0.483 5.37E-07e 1.10 (1.06–1.14) 2.24E-06e 0.95 (0.91–0.989) 1.31E-02f Ovarian, Lung Colorectal, Prostate
 rs115960372 1518494 C:T 0.104 6.94E-07e 1.19 (1.1–1.27) 2.97E-06e 0.90 (0.83–0.98) 1.29E-02f Prostate Lung
 rs2735944b 1304432 C:T 0.132 1.27E-06e 0.85 (0.80–0.90) 1.38E-07e Lung
 rs2853677b 1287194 A:G 0.400 1.33E-06e 1.11 (1.06–1.16) 1.54E-06e 0.97 (0.93–1.000) 4.99E-02f Lung Colorectal, Breast, Prostate
 rs12655062 1890877 G:A 0.354 1.65E-06e 1.12 (1.06–1.18) 3.53E-05 0.95 (0.92–0.98) 2.72E-03 Prostate Colorectal, Ovarian
 rs2736109b 1296759 C:T 0.392 2.99E-06e 1.11 (1.06–1.16) 5.88E-06e 0.96 (0.93–0.996) 3.08E-02f Lung Colorectal, Breast, Ovarian
 rs33961405b 1277577 A:G 0.491 1.20E-05e 1.11 (1.06–1.16) 4.55E-06e Lung
 rs55901723 1342154 T:C 0.232 2.14E-05 0.88 (0.84–0.93) 2.94E-06e Lung
 rs6861230 304003 T:C 0.042 2.70E-05 1.25 (1.13–1.37) 5.83E-06e Breast, Ovarian
POT1 (Chr. 7)
 rs116895242 123946403 T:A 0.041 5.21E-05 0.83 (0.77–0.90) 6.99E-06e Colorectal, Ovarian, Lung
 rs74986217 123465182 A:C 0.041 2.54E-04e 1.31 (1.16–1.48) 2.17E-05e Ovarian
TERF2 (Chr. 16)
 rs117496043c 69590365 C:T 0.003 4.28E-05 1.66 (1.33–2.06) 6.14E-06e Prostate
RTEL1 (Chr. 20)
 rs34978822c 62291599 C:G 0.015 2.14E-05 0.71 (0.62–0.82) 3.17E-06e Prostate, Lung
 rs114220381c 61477960 T:A 0.048 1.21E-04 1.31 (1.16–1.48) 1.13E-05e Prostate

Abbreviations: Chr.- chromosome; CI- confidence interval; MA- Minor Allele; OR- odds ratio; Ref- reference; SNP- single nucleotide polymorphism.

a

Results are presented for SNPs after pruning at r2<0.70.

b

SNPs that are directly measured and not imputed.

c

ASSET meta-analytical results for these SNPs are based on 4 cancer types rather than all 5 studies.

d

ASSET meta-analytical results for these SNPs are based on 2 cancer types rather than all 5 studies.

e

Gene level P-value thresholds based on the number of effective tests are: DCLER1B P-value<2.65×10−5; TERC P-value<2.45×10−5; GAR1 P-value<2.44×10−5; TERT-CLPTM1 P-value<1.32×10−5; POT1 P-value<2.94×10−5; TERF2 P-value<3.08×10−5; RTEL1 P-value<1.86×10−5.

f

Positive or negative associations with P-values between 0.01 and 0.05 are considered to be suggestive.